RXi Pharma Reports Positive Results With Its RNAi Platform - Quick Facts

(RTTNews) - RXi Pharmaceuticals Corp. (RXII) reported positive results from a collaboration with Biogazelle NV, a company with a longstanding track record and internationally recognized expertise in RNA gene expression analysis. RXi Pharma said, specifically-designed sd-rxRNAs based on RXi's proprietary, self-delivering RNAi platform demonstrated robust and potent reduction of the levels of lncRNAs in a target specific manner. The company said these findings expand the number of potential genes RXi is capable of targeting by approximately four fold.

Geert Cauwenbergh, CEO of RXi Pharma, said: "These results constitute a major boost to the value of our self-delivering platform by significantly expanding the breadth of therapeutic targets we can now pursue. This opens up additional business development and partnering opportunities with our sd-rxRNA platform, further supporting RXi's initiatives to build shareholder value."